Bio Rad Laboratories Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 11, 2022 / 09:30PM GMT
Rachel Marie Vatnsdal Olson - JPMorgan Chase & Co, Research Division - Analyst

Perfect. Good afternoon, everyone. This is Rachel Vatnsdal from the Life Science Tools and Diagnostics team here at JPMorgan. It's my pleasure to introduce our next company, Bio-Rad. So this session will be a 40-minute fireside chat. (Operator Instructions)

And with that, we can get started. So thank you, Norman, and Ilan and Andy for joining us today. To kick it off, we could just talk about, in general, the strength that you guys have seen in the past 2 years.

Questions and Answers:

Rachel Marie Vatnsdal Olson - JPMorgan Chase & Co, Research Division - Analyst

So the strength that you guys have seen has been in partly due to strong contribution from COVID-related sales. So with new variants likely to continue to emerge, how should we be thinking about the durability of your revenue in the coming year? And then what do you see for '23 and beyond?

Andrew J. Last - Bio-Rad Laboratories, Inc. - Executive VP & COO

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot